PMID

Data

Article Title

Organization

Structure-Based Design of an Iminoheterocyclicß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aß in Nonhuman Primates.

Merck Research Laboratories

 

Macrolide-type motilin receptor agonists: Assessment of the biological value of the 2- and 4-hydroxyl groups of acid-stable 8,9-anhydroerythromycin A 6,9-hemiacetals

TBA

 

Potent, acid-stable and orally active macrolide-type motilin receptor agonists, GM-611 and the derivatives

TBA

Identification of small molecule agonists of the motilin receptor.

Glaxosmithkline

9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety.

Kosan Biosciences

9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.

Kosan Biosciences

Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety.

Kosan Biosciences

Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.

Glaxosmithkline

Discovery of a new class of macrocyclic antagonists to the human motilin receptor.

Tranzyme Pharma

Discovery of a potent and novel motilin agonist.

Bristol-Myers Squibb Pharmaceutical Research Institute

The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.

Kosan Biosciences

Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical and Public Health Institute

The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.

Glaxosmithkline

Discovery of novel motilin antagonists: Conversion of tetrapeptide leads to orally available peptidomimetics.

Chugai Pharmaceutical

The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.

Glaxosmithkline

Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids.

Tranzyme Pharma

Synthesis and SAR of 1,3-disubstituted cyclohexylmethyl urea and amide derivatives as non-peptidic motilin receptor antagonists.

Johnson & Johnson Pharmaceutical Research & Development

Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.

Daiichi Sankyo

Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin.

Chugai Pharmaceutical